Valuation: Aclarion, Inc.

Market Cap 6.77M 6.05M 5.64M 5.13M 9.65M 656M 9.74M 67.75M 26.5M 333M 25.43M 24.88M 1.07B P/E 2026 *
-0.49x
P/E 2027 * -0.54x
Enterprise Value 6.77M 6.05M 5.64M 5.13M 9.65M 656M 9.74M 67.75M 26.5M 333M 25.43M 24.88M 1.07B EV / Sales 2026 *
61.9x
EV / Sales 2027 * 27.6x
Free-Float
76.02%
Yield 2026 *
-
Yield 2027 * -
1 day-1.70%
1 week-4.15%
Current month-4.15%
1 month-1.70%
3 months-22.74%
6 months-35.11%
Current year-49.78%
1 week 2.28
Extreme 2.28
2.48
1 month 2.28
Extreme 2.28
2.96
Current year 1.95
Extreme 1.95
9.36
1 year 1.95
Extreme 1.95
12.03
3 years 1.95
Extreme 1.95
89,552.67
5 years 1.95
Extreme 1.95
586,115.57
10 years 1.95
Extreme 1.95
586,115.57
Manager TitleAgeSince
Chief Executive Officer 59 15/09/2021
Director of Finance/CFO 60 02/09/2025
Corporate Officer/Principal - -
Director TitleAgeSince
Director/Board Member 69 01/01/2016
Director/Board Member 55 01/09/2016
Chairman 61 21/04/2022
Date Insider Type Main position Quantity % Market Cap. Importance
8/17/26 A Buy

Director

5,857 0.2379%
8/14/26 A Buy

Chief Financial Officer

10,000 0.4061%
8/13/26 A Buy

Director

7,500 0.3046%
Change 5-day change 1-year change 3-year change Capi.($)
-1.70%-4.15%-70.74%-100.00% 6.77M
-3.19%-3.19%+44.60%+87.98% 74.68B
-15.86%-16.67%+3.92%+50.90% 58.7B
-2.39%-2.05%+4.29%+31.33% 48.36B
-6.35%-8.35%+303.95%+651.28% 43.05B
+0.30%-3.71%+28.89%+30.33% 42.48B
-3.82%-4.32%+2.49%+101.36% 41.39B
-2.13%+1.07%+7.51%+50.31% 31.29B
-3.35%-6.35%-13.20%-17.22% 23.93B
-1.24%-11.97%-38.10%+311.13% 22.22B
Average -3.96%-2.61%+27.36%+119.74% 38.61B
Weighted average by Cap. -4.85%-1.88%+44.70%+136.42%

Financials

2026 *2027 *
Net sales 109K 97.76K 91.2K 82.84K 156K 10.6M 157K 1.09M 428K 5.39M 411K 402K 17.33M 245K 219K 204K 186K 349K 23.75M 353K 2.45M 959K 12.07M 921K 901K 38.81M
Net income -11.27M -10.07M -9.39M -8.53M -16.05M -1.09B -16.21M -113M -44.09M -555M -42.32M -41.4M -1.78B -12.46M -11.13M -10.38M -9.43M -17.74M -1.21B -17.92M -125M -48.75M -613M -46.78M -45.77M -1.97B
Net Debt - -
Projected Income Statement - Annual - Aclarion, Inc.
Logo Aclarion, Inc.
Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.
Employees
11
Date Price Change Volume
08/10/26 $2.310 -1.70% 31,589
07/10/26 $2.350 +2.62% 10,416
06/10/26 $2.290 -2.14% 30,912
05/10/26 $2.340 -1.68% 33,181
02/10/26 $2.380 -2.46% 15,749
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Aclarion, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.350USD
Average target price
7.625USD
Spread / Average Target
+224.47%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Aclarion, Inc.
  1. Stock Market
  2. Stocks
  3. ACON Stock